Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen s Q1 Revenues Up 10 Percent, Earnings Quadruple Thanks to Dynal Purchase

NEW YORK, April 29 (GenomeWeb News) - Invitrogen yesterday reported a 10-percent increase in revenues and quadrupled earnings for the first quarter of 2005.

 

Revenues for the quarter totaled $277.1 million, up from $251.3 million during the year-ago period. Both Invitrogen's BioDiscovery and BioProduction segments contributed to this increase.

 

Research and development expenses increased to $21.2 million from $15.7 million during the first quarter of 2004.

 

The company's net income increased to $47.1 million, or $.82 per share, from $10.5 million, or $.19 per share, during last year's first quarter. Included in this quarter's income is a gain of $21 million related to the hedging activity associated with Invitrogen's acquisition of Dynal.

 

As of March 31, Invitrogen had $1 billion in cash and investments.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.